adaptive immune resistance to intravesical bcg in nmibc: bcg-unresponsive clinical trials
Published 4 years ago • 835 plays • Length 19:31Download video MP4
Download video MP3
Similar videos
-
14:50
bcg unresponsive disease
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
11:45
emerging treatments for bcg unresponsive non-muscle invasive bladder cancer
-
21:04
bcg unresponsive non-muscle invasive bladder cancer
-
9:12
immunotherapy for nmibc: emerging and expanding indications
-
19:31
second line bladder cancer therapies when first line treatments fail
-
14:18
barriers to clinical trials for non-muscle invasive bladder cancer
-
1:08:14
urowebinar: bcg unresponsive disease how this definition impact your treatment decision making
-
21:28
bcg failure defining and managing difficult patients
-
50:41
management of bcg-unresponsive non-muscle invasive bladder cancer
-
19:16
checkpoint inhibitors for nmibc
-
10:44
earlier use of immune checkpoint inhibitors to adjuvant and non muscle invasive bladder cancer
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news
-
13:23
updating the definitions, endpoints, and clinical trial designs for bladder cancer
-
50:00
novel therapies to non muscle invasive bladder cancer
-
43:50
urowebinar: new treatments development in nmibc
-
17:36
management of high-grade t1 bladder cancer
-
18:43
lecture looking ahead - integrating immune checkpoint inhibitors into treatment paradigm for nmibc
-
21:37
non-muscle invasive bladder cancer: guidelines-based approach